| Record ID | marc_columbia/Columbia-extract-20221130-015.mrc:16266096:3708 |
| Source | marc_columbia |
| Download Link | /show-records/marc_columbia/Columbia-extract-20221130-015.mrc:16266096:3708?format=raw |
LEADER: 03708cam a22004454a 4500
001 7034955
005 20221130204126.0
008 081027t20092009nyua b 001 0 eng
010 $a 2008047209
020 $a9780387895192
020 $a0387895191
024 1 $a40016354807
035 $a(OCoLC)ocn265657867
035 $a(OCoLC)265657867
035 $a(NNC)7034955
035 $a7034955
040 $aDNLM/DLC$cDLC$dNLM$dUKM$dYDXCP$dC#P$dOrLoB-B
042 $apcc
050 00 $aQR185.8.T84$bT44 2009
060 10 $aW1$bAD559 v.647 2009
060 10 $aQW 568$bT3985 2009
082 00 $a616.07/9$222
245 00 $aTherapeutic targets of the TNF superfamily /$cedited by Iqbal S. Grewal.
260 $aNew York, N.Y. :$bSpringer Science+Business Media ;$aAustin, Tex. :$bLandes Bioscience,$c[2009], ©2009.
300 $axvii, 220 pages :$billustrations (some color) ;$c26 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
490 1 $aAdvances in experimental medicine and biology ;$vv. 647
504 $aIncludes bibliographical references and index.
505 00 $g1.$tOverview of TNF Superfamily: A Chest Full of Potential Therapeutic Targets /$rIqbal S. Grewal -- $g2.$tTherapeutic Interventions Targeting CD40L (CD154) and CD40: The Opportunities and Challenges /$rChe-Leung Law and Iqbal S. Grewal -- $g3.$tTargeting TNF for Treatment of Cancer and Autoimmunity /$rGautam Sethi, Bokyung Sung, Ajaikumar B. Kunnumakkara and Bharat B. Aggarwal -- $g4.$tTargeting of BAFF and APRIL for Autoimmunity and Oncology /$rMaureen C. Ryan and Iqbal S. Grewal -- $g5.$tThe Role of FasL and Fas in Health and Disease /$rMartin Ehrenschwender and Harald Wajant -- $g6.$tOX40 (CD134) and OX40L /$rMichael J. Gough and Andrew D. Weinberg -- $g7.$tTargeting CD70 for Human Therapeutic Use /$rTamar Boursalian, Julie McEarchern, Che-Leung Law and Iqbal S. Grewal -- $g8.$t4-1BB as a Therapeutic Target for Human Disease /$rSeung-Woo Lee and Michael Croft -- $g9.$tRank(L) as a Key Target for Controlling Bone Loss /$rAndreas Leibbrandt and Josef M. Penninger -- $g10.$tTargeting the LIGHT-HVEM Pathway /$rCarl F. Ware -- $g11.$tGITR: A Modulator of Immune Response and Inflammation /$rGiuseppe Nocentini and Carlo Riccardi -- $g12.$tTargeting CD30/CD30L in Oncology and Autoimmune and Inflammatory Diseases /$rEzogelin Oflazoglu, Iqbal S. Grewal and Hans Peter Gerber -- $g13.$tTumor Necrosis Factor Receptor Superfamily Member 21: TNFR-Related Death Receptor-6, DR6 /$rRobert Bensohop, Tao Wei and Songqing Na -- $g14.$tTrail and Other Trail Receptor Agonists as Novel Cancer Therapeutics /$rChristina Falschlehner, Tom M. Ganten, Ronald Koschny, Uta Schaefer and Henning Walczak -- $g15.$tTherapeutic Potential of VEGI/TL1A in Autoimmunity and Cancer /$rGautam Sethi, Bokyung Sung and Bharat B. Aggarwal.
650 0 $aTumor necrosis factor.$0http://id.loc.gov/authorities/subjects/sh87004016
650 0 $aTumor necrosis factor$xAgonists$xTherapeutic use.
650 12 $aTumor Necrosis Factors$xtherapeutic use.$0https://id.nlm.nih.gov/mesh/D048069Q000627
650 22 $aAutoimmune Diseases$xdrug therapy.$0https://id.nlm.nih.gov/mesh/D001327Q000188
650 22 $aInflammation$xdrug therapy.$0https://id.nlm.nih.gov/mesh/D007249Q000188
650 22 $aNeoplasms$xdrug therapy.$0https://id.nlm.nih.gov/mesh/D009369Q000188
650 22 $aReceptors, Tumor Necrosis Factor$xtherapeutic use.$0https://id.nlm.nih.gov/mesh/D018124Q000627
700 1 $aGrewal, Iqbal S.$0http://id.loc.gov/authorities/names/n2008184540
830 0 $aAdvances in experimental medicine and biology ;$vv. 647.$0http://id.loc.gov/authorities/names/n42001229
852 00 $boff,hsl$hQR185.8.T84$iT44 2009